Go Pro
NASDAQ:VANI

Vivani Medical Q1 2025 Earnings Report

Vivani Medical logo
$1.36 +0.02 (+1.11%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vivani Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
12:00AM ET

Vivani Medical Earnings Headlines

Vivani Medical (NASDAQ:VANI) Rating Increased to Hold at Wall Street Zen
Did you see the WSJ on 8-9?
On August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of Stansberry Research says one of them has returned more than Apple, Amazon, and the S&P 500 index combined in recent years. One well-known Wall Street money manager reportedly has roughly half his entire fund in this stock. Tilson's free write-up names the company and ticker, with no subscription required.tc pixel
Vivani Medical (VANI) Projected to Release Earnings on Wednesday
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) Solutions, Inc. (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity. These products aim to reduce complications associated with percutaneous biopsies while facilitating efficient sample collection and handling, helping clinicians deliver faster and more accurate diagnoses.

Vivani Medical serves a broad customer base that encompasses hospitals, outpatient imaging centers and pathology service providers across the United States. In addition to its direct‐sales model, the company has established distribution partnerships to extend its reach into select European and Latin American markets, supporting growing international adoption of its technologies.

Founded in 2016 and headquartered in the United States, Vivani Medical became a publicly traded company in mid-2021, listing its common stock on the Nasdaq Capital Market under the ticker symbol “VANI.” The company’s leadership team brings together experienced professionals in medical device innovation, regulatory affairs and commercial operations, driving ongoing efforts to expand its product pipeline and reinforce its position in the interventional radiology market.

View Vivani Medical Profile